help button home button The Oncologist http://theoncologist.alphamedpress.org/misc/eLetters.shtml
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harrison, L. B.
Right arrow Articles by Shasha, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harrison, L. B.
Right arrow Articles by Shasha, D.
The Oncologist, Vol. 7, No. 6, 492–508, December 2002
© 2002 AlphaMed Press

Impact of Tumor Hypoxia and Anemia on Radiation Therapy Outcomes

Louis B. Harrisona, Manjeet Chadhaa, Richard J. Hillb, Kenneth Hua, Daniel Shashaa

a Department of Radiation Oncology, Continuum Cancer Centers of New York, Beth Israel Medical Center and St. Luke’s-Roosevelt Hospital Center and The Albert Einstein College of Medicine, New York, New York, USA; b Ortho Biotech Products, L.P., Bridgewater, New Jersey, USA

Correspondence: Louis B. Harrison, M.D., The Charles and Bernice Blitman Department of Radiation Oncology, Beth Israel Medical Center, 10 Union Square East, New York, New York 10003, USA. Telephone: 212-844-8087; Fax: 212-844-8086; e-mail: lharrison{at}bethisraelny.org

Local recurrence remains a major obstacle to achieving cure of many locally advanced solid tumors treated with definitive radiation therapy. The microenvironment of solid tumors is hypoxic compared with normal tissue, and this hypoxia is associated with decreased radiosensitivity. Recent preclinical data also suggest that intratumoral hypoxia, particularly in conjunction with an acid microenvironment, may be directly or indirectly mutagenic. Investigations of the prognostic significance of the pretreatment oxygenation status of tumors in patients with head and neck or cervical cancer have demonstrated that increased hypoxia, typically designated in these studies as pO2 levels below 2.5-10 mm Hg, is associated with decreased local tumor control and lower rates of disease-free and overall survival. Hypoxia-directed therapies in the radiation oncology setting include treatment using hyperbaric oxygen, fluosol infusion, carbogen breathing, and electron-affinic and hypoxic-cell sensitizers. These interventions have shown the potential to increase the effectiveness of curative-intent radiation therapy, demonstrating that the strategy of overcoming hypoxia may be a viable and important approach. Anemia is common in the cancer population and is suspected to contribute to intratumoral hypoxia. A review of the literature reveals that a low hemoglobin level before or during radiation therapy is an important risk factor for poor locoregional disease control and survival, implying that a strong correlation could exist between anemia and hypoxia (ultimately predicting for a poor outcome). While having a low hemoglobin level has been shown to be detrimental, it is unclear as to exactly what the threshold for "low" should be (studies in this area have used thresholds ranging from 9-14.5 g/dl). Optimal hemoglobin and pO2 thresholds for improving outcomes may vary across and within tumor types, and this is an area that clearly requires further evaluation. Nonetheless, the correction of anemia may be a worthwhile strategy for radiation oncologists to improve local control and survival.

Key Words. Anoxia • Anemia • Radiation therapy • Neoplasms • Treatment outcome • Epoetin alfa




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
S. Kunigal, S. S. Lakka, P. Joseph, N. Estes, and J. S. Rao
Matrix metalloproteinase-9 Inhibition Down-Regulates Radiation-Induced Nuclear Factor-{kappa}B Activity Leading to Apoptosis in Breast Tumors
Clin. Cancer Res., June 1, 2008; 14(11): 3617 - 3626.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
R. Beck, B. Roper, J. M. Carlsen, M. C. Huisman, J. A. Lebschi, N. Andratschke, M. Picchio, M. Souvatzoglou, H.-J. Machulla, and M. Piert
Pretreatment 18F-FAZA PET Predicts Success of Hypoxia-Directed Radiochemotherapy Using Tirapazamine
J. Nucl. Med., June 1, 2007; 48(6): 973 - 980.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
R Berardi, C Braconi, G Mantello, M Scartozzi, S Del Prete, G Luppi, R Martinelli, M Fumagalli, G Valeri, I Bearzi, et al.
Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer
Ann. Onc., November 1, 2006; 17(11): 1661 - 1664.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. E. Hardee, M. O. Arcasoy, K. L. Blackwell, J. P. Kirkpatrick, and M. W. Dewhirst
Erythropoietin Biology in Cancer
Clin. Cancer Res., January 15, 2006; 12(2): 332 - 339.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. C. Winter, K. A. Shah, L. Campo, H. Turley, R. Leek, R. J. Corbridge, G. J. Cox, and A. L. Harris
Relation of Erythropoietin and Erythropoietin Receptor Expression to Hypoxia and Anemia in Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res., November 1, 2005; 11(21): 7614 - 7620.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. Escuin, E. R. Kline, and P. Giannakakou
Both Microtubule-Stabilizing and Microtubule-Destabilizing Drugs Inhibit Hypoxia-Inducible Factor-1{alpha} Accumulation and Activity by Disrupting Microtubule Function
Cancer Res., October 1, 2005; 65(19): 9021 - 9028.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Ning, C. Hartley, G. Molineux, and S. J. Knox
Darbepoietin Alfa Potentiates the Efficacy of Radiation Therapy in Mice with Corrected or Uncorrected Anemia
Cancer Res., January 1, 2005; 65(1): 284 - 290.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
M. Piert, H.-J. Machulla, M. Picchio, G. Reischl, S. Ziegler, P. Kumar, H.-J. Wester, R. Beck, A. J.B. McEwan, L. I. Wiebe, et al.
Hypoxia-Specific Tumor Imaging with 18F-Fluoroazomycin Arabinoside
J. Nucl. Med., January 1, 2005; 46(1): 106 - 113.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
L. Harrison and K. Blackwell
Hypoxia and Anemia: Factors in Decreased Sensitivity to Radiation Therapy and Chemotherapy?
Oncologist, November 1, 2004; 9(suppl_5): 31 - 40.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
K. Blackwell, P. Gascon, G. Sigounas, and L. Jolliffe
rHuEPO and Improved Treatment Outcomes: Potential Modes of Action
Oncologist, November 1, 2004; 9(suppl_5): 41 - 47.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
H. Ludwig
rHuEPO and Treatment Outcomes: The Preclinical Experience
Oncologist, November 1, 2004; 9(suppl_5): 48 - 54.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
C. A. Hudis, S. Van Belle, J. Chang, and K. Muenstedt
rHuEPO and Treatment Outcomes: the Clinical Experience
Oncologist, November 1, 2004; 9(suppl_5): 55 - 69.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. Kaufman, O. Scharf, J. Arbeit, M. Ashcroft, J. M. Brown, R. K. Bruick, J. D. Chapman, S. M. Evans, A. J. Giaccia, A. L. Harris, et al.
Proceedings of the Oxygen Homeostasis/Hypoxia Meeting
Cancer Res., May 1, 2004; 64(9): 3350 - 3356.
[Abstract] [Full Text] [PDF]


Home page
DTBHome page
Epoetins and {blacktriangledown}darbepoetin alfa in malignant disease
DTB, March 1, 2004; 42(3): 21 - 24.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. Bettegowda, L. H. Dang, R. Abrams, D. L. Huso, L. Dillehay, I. Cheong, N. Agrawal, S. Borzillary, J. M. McCaffery, E. L. Watson, et al.
Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria
PNAS, December 9, 2003; 100(25): 15083 - 15088.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
M. J. Weiss
New Insights Into Erythropoietin and Epoetin Alfa: Mechanisms of Action, Target Tissues, and Clinical Applications
Oncologist, December 1, 2003; 8(90003): 18 - 29.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl

Copyright © 2002 by AlphaMed Press.